BioCentury | Apr 14, 2017
Company News

2-BBB Medicines, TTY Biopharm deal

...commercialize 2-BBB’s multiple sclerosis candidate 2B3-201 . 2-BBB will grant the JV exclusive rights to 2B3-201...
...stake in the JV; TTY will invest NT$240 million ($7.8 million) for the remaining stake. 2B3-201...
BioCentury | Sep 29, 2014
Clinical News

2B3-201: Phase I data

...2B3-201 were well tolerated with no serious adverse events reported. Subjects received an infusion of 2B3-201...
...healthy female volunteers and 18 MS patients. to-BBB technologies B.V. , Leiden, the Netherlands Product: 2B3-201...
BioCentury | Dec 23, 2013
Clinical News

2B3-201: Phase I started

...2B3-201, placebo and methylprednisolone in 1-week intervals. to-BBB technologies B.V. , Leiden, the Netherlands Product: 2B3-201...
BioCentury | Jan 21, 2013
Product Development

Solving the ALS maze

...molecule inducer of heat shock protein gene expression Start Ph I 2013 to-BBB technologies B.V. 2B3-201...
BioCentury | Jul 23, 2012
Clinical News

to-BBB preclinical data

...government agency Agentschap NL granted to-BBB a €500,000 ($611,351) Innovation Credit for preclinical development of 2B3-201...
...apply for additional credits for clinical development. to-BBB technologies B.V. , Leiden, the Netherlands Product: 2B3-201...
...Autoimmune Indication: Treat multiple sclerosis (MS) In a rat model of MS, 10 mg/kg IV 2B3-201...
BioCentury | Apr 23, 2012
Company News

to-BBB, Michael J. Fox Foundation For Parkinson's Research neurology news

...to-BBB received a grant from the foundation to conduct preclinical testing of 2B3-201 to treat Parkinson's...
Items per page:
1 - 6 of 6